Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-12-29 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 90% confidence The document text is extremely short (74 characters) and contains no substantive content, financial data, or any identifiable report information. It only includes a placeholder for an omitted picture and no text that could indicate the nature of the filing. Given the lack of content, this document cannot be classified as any specific report type and fits best as a Regulatory Filing (RNS) by default, as it does not meet criteria for any other category.
2020-12-29 English
Loss of share certificates
Regulatory Filings
2020-12-17 English
NATCO launches anti blood clot tablet Rivaroxaban in India
Regulatory Filings
2020-12-17 English
Press Release
Regulatory Filings Classification · 90% confidence The document text is extremely short (118 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report title, no regulatory references, or any indication of the document's purpose. Given the lack of content, it cannot be classified as a full report or detailed filing. According to the rules, such minimal content with no report text defaults to Regulatory Filings (RNS) as a fallback category.
2020-12-17 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of Related Party Transactions for the half year ended September 30, 2020, submitted pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It includes detailed financial data on transactions with subsidiaries, key management personnel, and other related parties. The document is addressed to stock exchanges and is a regulatory compliance filing. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement of voting results or management changes. It is a specific regulatory disclosure related to related party transactions, which falls under the category of Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance document under SEBI regulations.
2020-12-10 English
Disclosure of Related Party Transactions for the half year ended September 30, 2020
Regulatory Filings
2020-12-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.